Please login to the form below

Not currently logged in
Email:
Password:

Boston Biomedical appoints commercial head

Patricia Andrews joins from Incyte Corporation

Boston Biomedical has named Pfizer veteran Patricia Andrews as chief commercial officer.

Andrews joins Boston Biomedical – a subsidiary of Japanese firm Dainippon Sumitomo Pharma – to bulk up its commercialisation efforts as lead drug candidate BBI608 nears phase III completion for use in metastatic colorectal cancer.

She previously spent 17 years at Pfizer, rising to VP and general manager of US oncology, before joining from oncology/inflammation-focused Incyte Corporation where she served as executive VP and chief commercial officer.

At Incyte, she established the company's commercial operations and successfully launched Jakafi (ruxolitinib) for myelofibrosis as part of a collaboration with Novartis.

Andrews is expected to perform a similar role at Boston, which has so far been focused on research.

"I am very excited about this opportunity and look forward to building a world-class commercial oncology team at Boston Biomedical," she said.

21st November 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics